Switch theme
Sign up to access all valuation multiples
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
2006
47
LTM Revenue $3.9M
LTM EBITDA -$1.0M
$62.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Marinomed Biotech has a last 12-month revenue (LTM) of $3.9M and a last 12-month EBITDA of -$1.0M.
In the most recent fiscal year, Marinomed Biotech achieved revenue of $5.3M and an EBITDA of -$8.1M.
Marinomed Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Marinomed Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.9M | XXX | $5.3M | XXX | XXX | XXX |
| Gross Profit | $3.9M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 21% | XXX | XXX | XXX |
| EBITDA | -$1.0M | XXX | -$8.1M | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -151% | XXX | XXX | XXX |
| EBIT | $5.5M | XXX | -$7.8M | XXX | XXX | XXX |
| EBIT Margin | 141% | XXX | -146% | XXX | XXX | XXX |
| Net Profit | $0.4M | XXX | -$17.3M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | -325% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $29.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Marinomed Biotech's stock price is EUR 16 (or $19).
Marinomed Biotech has current market cap of EUR 29.3M (or $33.0M), and EV of EUR 55.9M (or $62.8M).
See Marinomed Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62.8M | $33.0M | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Marinomed Biotech has market cap of $33.0M and EV of $62.8M.
Marinomed Biotech's trades at 11.8x EV/Revenue multiple, and -7.8x EV/EBITDA.
Equity research analysts estimate Marinomed Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marinomed Biotech has a P/E ratio of 78.8x.
See valuation multiples for Marinomed Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33.0M | XXX | $33.0M | XXX | XXX | XXX |
| EV (current) | $62.8M | XXX | $62.8M | XXX | XXX | XXX |
| EV/Revenue | 16.0x | XXX | 11.8x | XXX | XXX | XXX |
| EV/EBITDA | -64.4x | XXX | -7.8x | XXX | XXX | XXX |
| EV/EBIT | 11.3x | XXX | -8.0x | XXX | XXX | XXX |
| EV/Gross Profit | 16.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 78.8x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMarinomed Biotech's last 12 month revenue growth is 6%
Marinomed Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Marinomed Biotech's rule of 40 is -34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Marinomed Biotech's rule of X is -10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Marinomed Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | -8% | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -151% | XXX | XXX | XXX |
| EBITDA Growth | -489% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -34% | XXX | -145% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -10% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 167% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marinomed Biotech acquired XXX companies to date.
Last acquisition by Marinomed Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Marinomed Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Marinomed Biotech founded? | Marinomed Biotech was founded in 2006. |
| Where is Marinomed Biotech headquartered? | Marinomed Biotech is headquartered in Austria. |
| How many employees does Marinomed Biotech have? | As of today, Marinomed Biotech has 47 employees. |
| Is Marinomed Biotech publicy listed? | Yes, Marinomed Biotech is a public company listed on WBO. |
| What is the stock symbol of Marinomed Biotech? | Marinomed Biotech trades under MARI ticker. |
| When did Marinomed Biotech go public? | Marinomed Biotech went public in 2018. |
| Who are competitors of Marinomed Biotech? | Similar companies to Marinomed Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Marinomed Biotech? | Marinomed Biotech's current market cap is $33.0M |
| What is the current revenue of Marinomed Biotech? | Marinomed Biotech's last 12 months revenue is $3.9M. |
| What is the current revenue growth of Marinomed Biotech? | Marinomed Biotech revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Marinomed Biotech? | Current revenue multiple of Marinomed Biotech is 16.0x. |
| Is Marinomed Biotech profitable? | Yes, Marinomed Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Marinomed Biotech? | Marinomed Biotech's last 12 months EBITDA is -$1.0M. |
| What is Marinomed Biotech's EBITDA margin? | Marinomed Biotech's last 12 months EBITDA margin is -25%. |
| What is the current EV/EBITDA multiple of Marinomed Biotech? | Current EBITDA multiple of Marinomed Biotech is -64.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
